Chemistry:Zanzalintinib
Zanzalintinib (also known as XL092) is an inhibitor of several receptor tyrosine kinases, including VEGFR2, MET, and the TAM kinases AXL, and MERTK . It could potentially be used to treat colorectal cancer and renal cell carcinoma (RCC). It is being developed by Exelixis.[1][2]
STELLAR-303 is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.[3] The trial found that the combination of zanzalintinib and atezolizumab improved overall survival compared to regorafenib.[4]
STELLAR-304 (NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC).[5]
References
- ↑ "481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab". Annals of Oncology 33: S760. September 2022. doi:10.1016/j.annonc.2022.07.609. ISSN 0923-7534.
- ↑ "Stellar 002" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-002.
- ↑ "Stellar 303" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-303.
- ↑ "Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial" (in English). Lancet 406 (10517): 2360–2370. November 2025. doi:10.1016/S0140-6736(25)02025-2. PMID 41130252.
- ↑ "Stellar 304" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-304.
 |  |
